Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares ...

China’s Alebund Pharmaceuticals announced positive top-line Phase III results highlighting that the use of AP301 demonstrated a statistically-significant and clinically-meaningful improvement in serum ...

Planning and recruitment issues can compound during this critical phase of the drug development process. Gen Li, president ...

A federal district court in Delaware ruled that Viatris’ product, currently awaiting approval from the US Food and Drug Administration (FDA), does not infringe on Novo Nordisk’s patent for the ...

Kling Bio has entered a partnership and licence option agreement with Sanofi to discover neutralising antibodies and epitopes.

The Swiss company, which markets Elevidys abroad, said it believes the benefit-risk balance to treatment remains positive in ...

China’s healthcare sector is showing strong signs of recovery, driven by renewed investor confidence, supportive government policies, and a wave of innovation in diagnostics and therapies.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

(Alliance News) - AstraZeneca PLC on Thursday said its investigational complement C5 inhibitor gefurulimab showed statistically significant results in treating adults with a form of generalised ...

Enterprise tech, pharma/healthcare, consumer and financial services remain the firm’s focus investment areas. Kukreja ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer ...